Skip to content
Open in App
Regeneron Pharma logo

Regeneron Pharma

web2

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes...

Symbol · REGNUS
Company profile

About

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Positive Phase 3 olatorepatide obesity results reported

KEY STEP

Regeneron announced positive topline results from Hansoh Pharma’s Phase 3 trial of olatorepatide in 604 adults with obesity or overweight in mainland China. Patients achieved up to 19% mean body weight loss at week 48, and the trial met its coprimary endpoints.

Roadmap reference

Phase 3 fianlimab melanoma trial misses primary endpoint

KEY STEP

Regeneron reported that its Phase 3 trial of fianlimab plus cemiplimab in first line unresectable or metastatic melanoma did not achieve statistical significance for the primary progression free survival endpoint versus pembrolizumab. The high dose combination showed median progression free survival of 11.5 months versus 6.4 months for pembrolizumab, while a separate Phase 3 comparison with Opdualag remained ongoing.

Roadmap reference

FDA approves Pasatru for adults with fibrodysplasia ossificans progressiva

KEY STEP

The United States FDA approved Pasatru, also known as garetosmab, to reduce formation of new heterotopic ossification lesions and clinician assessed flare ups in adults with fibrodysplasia ossificans progressiva. The approval was based on the Phase 3 OPTIMA trial, in which the two tested doses reduced new heterotopic ossification lesions by 90% and 94% versus placebo at 56 weeks.

Roadmap reference
People

Company team

LS

Leonard S. Schleifer

Co-Founder, President, CEO & Co-Chairman

Company leadership profile.

GD

George D. Yancopoulos

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Company leadership profile.

GL

George L. Sing

Independent Director

Company leadership profile.

AF

Arthur Frederick Ryan

Independent Director

Company leadership profile.

CA

Christine Ann Poon

Lead Independent Director

Company leadership profile.

JL

Joseph L. Goldstein

Independent Director

Company leadership profile.

MS

Michael S. Brown

Independent Director

Company leadership profile.

BL

Bonnie L. Bassler

Independent Director

Company leadership profile.

HY

Huda Y. Zoghbi

Independent Director

Company leadership profile.

NA

N. Anthony Coles

Independent Director

Company leadership profile.

CB

Craig B. Thompson

Independent Director

Company leadership profile.

KW

Kathryn W. Guarini

Independent Director

Company leadership profile.

DP

David P. Schenkein

Director

Company leadership profile.

Expert coverage

1 expert evaluated Regeneron Pharma.

Orbitrum research

Experts evaluating Regeneron Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment